Page last updated: 2024-11-06

cr 1392

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID65852
CHEMBL ID2107668
SCHEMBL ID2107749
MeSH IDM0138785

Synonyms (17)

Synonym
tomoglumide
4-[(3,4-dimethylbenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
pentanoic acid, 4-((3,4-dimethylbenzoyl)amino)-5-(dipentylamino)-5-oxo-
cr-1392
4-((3,4-dimethylbenzoyl)amino)-5-(dipentylamino)-5-oxopentanoic acid
(+-)-4-(3,4-dimethylbenzamido)-n,n-dipentylglutaramic acid
tomoglumide [inn]
cr 1392
4ao61i7slb ,
unii-4ao61i7slb
97964-54-0
CHEMBL2107668
4-(3,4-dimethylbenzoylamino)-5-(di-n-pentylamino)-5-oxopentanoic acid
SCHEMBL2107749
Q27259349
DTXSID40869310
n~2~-(3,4-dimethylbenzoyl)-n,n-dipentyl-alpha-glutamine

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the isolated acini, CR 1392 caused a parallel rightward shift of the dose-response curve for amylase secretion stimulated by cholecystokinin octapeptide (CCK-8)."( Effects of a new proglumide analogue CR 1392 on pancreatic exocrine secretion in the rat.
Baba, S; Fujii, M; Fujisawa, T; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1989
)
0.86
" Atropine shifted the dose-response curve of CCK-OP in pylorus, duodenum and antrum to the right suggesting a neural action of CCK-OP."( Effect of the novel cholecystokinin receptor antagonist CR-1392 on cholecystokinin-induced antroduodenal and pyloric motor activity in vivo.
Allescher, HD; Daniel, EE; Fox, JE; Kostolanska, F; Rovati, LA, 1989
)
0.28
" Proglumide and CR-1392 caused a rightward and parallel shift, respectively, in the dose-response curve of CCK8 stimulated pancreatic protein secretion in anesthetized rats, demonstrating a competitive-like mechanism of inhibition."( The anti-CCK effect of glutaramic acid derivatives in anesthetized and conscious rats.
Nagy, I; Pap, A; Takács, T; Varró, V, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]